Business Daily Media

Business Marketing

.

Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan

  • Written by ACN Newswire - Press Releases

Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan

TOKYO, Mar 31, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K. a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., (known as MSD outside the United States and Canada) announced today that Eisai has submitted an application in Japan for the additional indication of its in-house discovered and developed multiple receptor tyrosine

Read more //?#

Popular

Deliveroo signs up 10,000th restaurant

Deliveroo, the leading food delivery company, has announced a further increase in the selection of popular restaurants and takeaways available on the platform in Australia.  The British ‘unicorn’ reveals that it now works with...

3 of the best options to pay for your new car in 2022

The Australian car market is as strong as it has ever been before. While the pandemic meant there was a shortage of new car stock coming into the market the used car market grew exponentially. Now, we have more new cars coming i...

Not surviving, thriving: top tips to help your business move forward in 2022

As Australia and New Zealand continues to reopen for business, companies need to stop bunkering down and start gearing up for growth, writes Access4 Managing Director, Tim Jackson ‘Things can only get better’ as pop band D:...